Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Fortis Healthcare - Balance sheet improving, valuations reasonable; upgrade to Hold - Anand Rathi

Posted On: 2013-02-13 20:21:57

Results in line with estimates. Fortis Healthcare's (Fortis) revenue grew 154.5% yoy to Rs. 15.4bn, better than our expected Rs. 14.9bn. Its reported EBITDA margin declined 380bps yoy to 9.9% (versus our estimated 10.3%) on payment of service fees to Religare Health Trust (RHT). The company reported exceptional gain of Rs. 9.7bn, pertaining to gain on dilution of stake in RHT. Adjusting for this gain, the company reported net loss of Rs. 433m.

Healthy growth across segments. Strong revenue growth was largely driven by 20% increase in revenue from India hospitals business with improved EBITDA margin of 15.8%. Domestic diagnostics business (Super Religare Laboratories) grew 12% yoy with 370bps yoy improvement in EBITDA margin to 10.3% (down ~400bps qoq). International business revenue came at Rs. 8.2bn, up 6.4% qoq. EBITDA margin in international business sustained at ~13%.

Our take. We believe that inflow of cash from dilution of stake in RHT, divestment of Dental Corp. subsidiary by Mar'13 and issue of equity shares through the IPP route would help the company strengthen its balance sheet substantially by bringing down D/E level to 0.5x by FY14e. Further, the proportion of revenue from India business would move up to 70%+ from ~50% currently post divestment of Dental Corp., which would bring focus back to India. We maintain revenue estimates, but lower PAT marginally to factor in higher service fees to RHT, which could hit EBITDA. Management focus is currently on strengthening balance sheet and no M&A is expected in near future, which is a positive in our view.

The stock is currently trading at EV/EBITDA valuations of 13.5x FY14e and 10.8x FY15e. We upgrade the stock to Hold from Sell on improving balance sheet and reasonable valuations. We also raise our target price to Rs. 118 (earlier Rs. 110), based on 14x FY14e EBITDA and Rs. 21 for stake in RHT. Risks. Delay in execution of expansion projects and integration of international operations.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Yes Bank - 3QFY2016 Result Update - Angel Broking
Maruti Suzuki - 3QFY2016 Result Update - Angel Broking
Power Grid Corporation of India - 3QFY2016 Result Update - Angel Broking
UltraTech Cement - 3QFY2016 Result Update - Angel Broking
Hindustan Media Ventures - 3QFY2016 Result Update - Angel Broking
Hindustan Zinc - 3QFY2016 Result Update - Angel Broking
Linc Pen & Plastics Ltd (LPPL) 3QFY2016 Results: Angel Broking
Sadbhav Engineering Ltd 3QFY2016 Results: Angel Broking
Buy Neuland Labs: AnandRathi Institutional Research
Radico Khaitan 3QFY2016 Results - Earnings outperform, top-line flat YoY - Angel Broking
Dishman Pharma 3QFY2016 Results: Angel Broking
Lupin 3QFY2016 Results: Angel Broking
Eicher Motors 4QFY2016 Results: Angel Broking
Buy Escorts: AnandRathi Institutional Research
Cadila Healthcare 3QFY2016 Results: Angel Broking
Tata Steel 3QFY2016 Results - EBITDA disappoints led by poor performance in Europe - Angel Broking
Views on Visaka Industries 3QFY2016 Result: Angel Broking
Views on Sanofi India 4QCY2015 Results: Angel Broking
Views on Bajaj Auto 3QFY2016 Results: Angel Broking
BUY Aegis Logistics: AnandRathi Institutional Research
BUY Century Plyboards: AnandRathi Institutional Research
Views on Transport Corporation of India Ltd 3QFY2016 Result: Angel Broking
Views on Tech Mahindra 3QFY2016 Results: Angel Broking
BUY Indoco Remedies - AnandRathi Institutional Research
Buy IRB Infrastructure : AnandRathi Institutional Research
Buy Granules India: AnandRathi Institutional Research
Views on Blue Star 3QFY2016 Results: Angel Broking
Views on Larsen & Toubro 3QFY2016 Results: Angel Broking
Views on United Phosphorus Ltd 3QFY2016 Results: Angel Broking
Views on Indoco Remedies 3QFY2016 Results: Angel Broking
Views on Yes Bank 3QFY2016 Results: Angel Broking
Views on TVS Motors Company 3QFY2016 Results: Angel Broking
Views on Maruti Suzuki India Ltd 3QFY2016 Results: Angel Broking
Views on ICICI Bank 3QFY2016 Results : Angel Broking
Views on Gujarat Pipavav Port 3QFY2016 Results: Angel Broking
Views on Jyothy Laboratories 3QFY2016 Result: Angel Broking
Views on HDFC Ltd 3QFY2016 Result: Angel Broking
BUY Unichem Labs: AnandRathi Institutional Research
Views on Power Grid Corporation (PGCIL) 3QFY2016 Result: Angel Broking
Views on Bharat Electronics Ltd. (BEL) 3QFY2016 Result: Angel Broking
Views on Kirloskar Oil Engines 3QFY2016 Result: Angel Broking
BUY Ashoka Buildcon: AnandRathi Institutional Research
Views on LG Balakrishnan & Bros 3QFY2016 Result: Angel Broking
Views on Hindustan Media Ventures Limited 3QFY2016 Result: Angel Broking
SELL Mindtree - AnandRathi Institutional Research
BUY Mastek: AnandRathi Institutional Research
Hold Cyient: AnandRathi Financial Services
Views on HCL Technologies 2QFY2016 Result: Angel Broking
Views on Rallis India 3QFY2016 Result: Angel Broking
Views on Wipro 3QFY2016 Result: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014